The China National Drug Administration have granted rapid approval of Alecensa® as a monotherapy treatment for patients with ALK-positive, advanced non-small cell lung cancer.
Browsing: non-small-cell lung cancer
Cost–effectiveness and budget impact of lung cancer immunotherapy in South America: strategies to improve access
Immune checkpoint inhibitors revolutionized the treatment of non-small-cell lung cancer, although their costs are a limitation; find out more in this article from Immunotherapy.
Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice
Find out more about the utility of clinical characteristics in the selection of patients with advanced NSCLC as potential candidates for single-agent anti-PD-1/PD-L1 immunotherapy in this open access Future Oncology review article.
NICE have approved Alecensa for use on the NHS, following positive data from a Phase II trial, including a reduced risk of brain metastasis.
A first-of-its-kind vaccine, termed AST-VAC2, has moved into a Phase I clinical trial for non-small cell lung cancer patients.
Results of the KEYNOTE-042 study have demonstrated pembrolizumab to be more effective in most patients with the most common form of lung cancer, in comparison to the current standard-of-care, namely, chemotherapy.
Roche has announced results from its Phase III IMpower130 trial. The findings demonstrate that Tecentriq® plus chemotherapy helped individuals with metastatic non-squamous NSCLC, who lived significantly longer compared with those who received chemotherapy alone
AstraZeneca and MedImmune have announced results of their Phase III PACIFIC trial.
Keytruda® has significantly improved overall survival and progression-free survival as a first-line treatment for squamous non-small cell lung cancer in the Phase III KEYNOTE-407 trial.
AstraZeneca (DE, USA) and Medimmune (MD, USA), recently announced results from the ARCTIC trial in third-line non-small cell lung cancer (NSCLC).